Table 6 The completed and recruiting clinical trials of EBV-associated NPC
From: Viral oncogenesis in cancer: from mechanisms to therapeutics
Conditions | Interventions | Phases | Patients (N) | NCT number | Status | Study period | URL |
|---|---|---|---|---|---|---|---|
EBV+ NPC | DNR.NPC-specific T cells | PHASE 1 | 14 | NCT02065362 | ACTIVE_NOT_RECRUITING | 2015/02/01 −2033/02/01 | |
Locally advanced NPC with detectable EBV DNA | Camrelizumab Nimotuzumab | PHASE 3 | 459 | NCT05772208 | RECRUITING | 2022/01/01 −2028/01/01 | |
Locally advanced NPC with detectable EBV DNA | Toripalimab | PHASE 2 | 198 | NCT05628922 | RECRUITING | 2022/07/02 −2027/07/01 | |
EBV+ Lymphoma EBV+ Malignancies | MABEL CTLs Cyclophosphamide Fludarabine | PHASE 1 | 42 | NCT02287311 | RECRUITING | 2015/02/01 −2029/03/01 | |
EBV+ NPC | EBV CAR-T-cell EBV TCR-T-cell | EARLY_PHASE 1 | 24 | NCT05587543 | RECRUITING | 2022/12/28 −2030/10/01 | |
EpCAM+ patients with Advanced Solid Tumors | EpCAM CAR-T cells | PHASE 1 | 30 | NCT02915445 | ACTIVE_NOT_RECRUITING | 2016/07/01 −2025/07/01 | |
R/R EBV+ NPC | EBV CAR-T/TCR-Tcell | EARLY_PHASE 1 | 24 | NCT05587543 | RECRUITING | 2022/12/28 −2030/10/01 |
